Identification of a novel WT1-derived peptide which induces human leucocyte antigen-A24-restricted anti-leukaemia cytotoxic T lymphocytes.
We previously reported the establishment of a Wilms' tumour (WT)1-derived peptide (CMTWNQMNL)-specific and human leucocyte antigen (HLA)-A24-restricted anti-leukaemia cytotoxic T lymphocyte (CTL) line, TAK-1. In this study, we have established a novel WT1-derived peptide (RWPSCQKKF)-specific CD8+ CTL line, designated NIM-1. NIM-1 lysed HLA-A24-positive leukaemia cells, but not HLA-A24-negative leukaemia cells or normal cells. The effects of TAK-1 and NIM-1 on cytotoxicity against leukaemia cells were not synergistic, suggesting that recognition of a single epitope on the tumour-specific antigen by CTLs is sufficient to exert maximal cytotoxic activity against tumour cells.
Azuma
Taichi
T
First Department of Internal Medicine, Ehime University School of Medicine, Shinegobu, Ehime, Japan.
Makita
Masanori
M
Ninomiya
Kanji
K
Fujita
Shigeru
S
Harada
Mine
M
Yasukawa
Masaki
M
D018414:CD8-Positive T-Lymphocytes / Q000276:immunology*; D002460:Cell Line; D003602:Cytotoxicity, Immunologic; D015234:HLA-A Antigens / Q000276:immunology*; D059871:HLA-A24 Antigen; D006801:Humans; D007938:Leukemia / Q000276:immunology*; D014407:Tumor Cells, Cultured; D025721:WT1 Proteins / Q000276:immunology*
D015234:HLA-A Antigens; D059871:HLA-A24 Antigen; D025721:WT1 Proteins